New research supports risk-based prostate cancer screening

Data from the world’s largest prostate cancer screening study provides further evidence to support the introduction of a targeted screening programme for the disease, say researchers.

Sat, 2 Jul 2022
Prostate CancerDataERSPC

In 2009, the European Randomised Study of Screening for Prostate Cancer (ERSPC) showed that screening can reduce mortality from prostate cancer by between 20-35 percent. But the earlier and more frequent diagnoses which screening enables, also mean men spend longer living with their cancer – and concerns have persisted about the impact of this on their quality of life.